Novonesis Acquires dsm-firmenich’s Portion of the Feed Enzyme Alliance
In a significant move, Novonesis has finalized a deal with dsm-firmenich to end the Feed Enzyme Alliance. The proposed transition will see Novonesis take complete control of the sales and distribution functions, all for a notable total cash outlay of EUR 1.5 billion. This strategic acquisition follows over 25 years of partnership, with dsm-firmenich undergoing a repositioning that paved the way for this opportunity.
The decision to acquire is closely tied to Novonesis’ growth objectives, allowing the company to increase its footprints in the animal biosolutions value chain. This acquisition is set to create financial benefits, enhancing revenues, EBITDA margins, and excluding amortization, while tapping into attractive revenue synergies.
Leadership Insights on the Acquisition
Ester Baiget, the CEO of Novonesis, shared her enthusiasm: "We are thrilled to announce our acquisition of the complete Feed Enzyme Alliance. The world’s protein demands are rising, accompanied by increasing land and water shortages, which necessitates innovative solutions." Baiget emphasized that with this strategic expansion in the animal biosolutions space, Novonesis can enhance its ability to deliver sustainable and value-adding biosolutions to customers.
Dimitri de Vreeze, CEO of dsm-firmenich, expressed confidence in the ongoing success of the alliance under Novonesis’ leadership. He stated, "The Alliance has led to immense success for both parties, establishing a global leadership in feed enzymes. I believe this business will flourish with Novonesis at the helm and I look forward to continuing our commercial relations with their Animal Nutrition & Health sector."
Strategic Benefits of the Acquisition
Vertical Integration of the Value Chain
By acquiring dsm-firmenich’s share, Novonesis is poised to achieve comprehensive integration of the value chain, amplifying its product innovation and production capabilities. This unified approach is anticipated to enhance the ability to cater efficiently to both existing and new customers with substantial insights into key markets and technological advancements that spur further innovation.
Strengthened Industry Position
With the successful merging of Novozymes and Chr. Hansen, Novonesis now stands as a forerunner in animal biosolutions, boasting a streamlined go-to-market strategy and robust technological edge. This agreement will greatly increase Novonesis' customer outreach and broaden its range of leading biosolutions, which include both enzymes and probiotics aimed at animal health and nutrition.
Vision for Growth and Financial Impact
The market for animal biosolutions is anticipated to grow at a mid-single digit CAGR, driven by an escalating global appetite for protein, coupled with ecological pressures. Novonesis projects that this acquisition will boost its sales growth by a low-single-digit CAGR over market growth rates, while also enhancing adjusted EBITDA margins.
The financial profile of the acquired enterprise promises growth synergies and operational efficiency, with near-term expectations including a close to 3% revenue boost at the group level and approximately 5% within the Planetary Health division in the first year post-acquisition.
Timeline and Future Expectations
Pending regulatory approvals, Novonesis anticipates the deal will be concluded within the year ahead. The financing structure for this acquisition will lean entirely on debt, backed by strong expected cash-flow generation that aims for a steady reduction in net debt to EBITDA ratios.
About Novonesis
Novonesis is at the forefront of pioneering biosolutions globally. Leveraging the capabilities of microbiology and science, the firm is revolutionizing production methods across more than 30 industries, impacting clients and the planet alike. With a talented team of around 10,000 employees, Novonesis collaborates with its partners and customers to unlock new potentials through biological innovations.
About the Feed Enzyme Alliance
The Feed Enzyme Alliance thrives on the collective strengths of Novonesis and dsm-firmenich. Novonesis brought a wealth of knowledge in high-quality enzyme development, while dsm-firmenich contributed a formidable sales network, giving access to key industry clients. The partnership evolved based on mutual trust, performance, and strong business relationships, benefiting both parties significantly.
About dsm-firmenich
Dsm-firmenich excels as an innovator in nutrition, health, and beauty sectors, continuously reinventing and combining vital nutrients, flavors, and fragrances for a growing global populace. With a commitment to sustainability and a diverse, skilled workforce, dsm-firmenich operates in around 60 countries and boasts annual revenues exceeding €12 billion.
Frequently Asked Questions
What prompted Novonesis to acquire dsm-firmenich's share?
The acquisition aligns with Novonesis’ growth strategy, enhancing its presence in the animal biosolutions market.
What is the financial impact of this acquisition?
The deal is expected to generate revenue increases, improved EBITDA margins, and adjusted EPS, all while fostering innovative growth.
How does this acquisition affect Novonesis' position in the market?
It consolidates Novonesis as a leader in animal biosolutions, enhancing its product offerings and customer reach.
What future expectations does Novonesis have regarding this acquisition?
Novonesis anticipates regulatory approval in the forthcoming year, aiming for enhanced growth and operational efficiencies.
How does Novonesis plan to finance the acquisition?
The acquisition will be financed through debt, with plans for significant cash generation aimed at reducing net debt ratios.
